Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$4.58
+2.3%
$5.03
$3.42
$7.20
$251.28M1.751.57 million shs708,073 shs
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
$1.19
-0.8%
$1.27
$0.86
$3.78
$262.48M0.313.26 million shs1.38 million shs
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$1.71
+0.6%
$1.81
$1.32
$2.72
$248.27M1.71192,014 shs16,498 shs
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
$11.00
$11.00
$0.00
$12.48
$62.26M-0.112 shs99 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
+2.35%+7.39%-14.80%+14.09%-6.63%
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-0.83%-0.83%-11.85%-17.36%-42.79%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
+0.59%+4.91%-7.82%+14.00%-13.64%
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
0.00%0.00%0.00%0.00%+10.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.2092 of 5 stars
0.01.00.00.01.60.80.6
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
3.0491 of 5 stars
4.51.00.00.00.63.30.6
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
0.9261 of 5 stars
3.51.00.00.00.00.00.0
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
2.90
Moderate Buy$8.44609.62% Upside
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.00
Buy$7.00309.36% Upside
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest VHAQ, ALLO, IMMP, and ACB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $4.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$9.00 ➝ $7.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $10.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$10.00 ➝ $10.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$12.00 ➝ $9.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$246.72M1.04$0.63 per share7.31$7.78 per share0.59
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
$20K13,014.44N/AN/A$2.01 per share0.59
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$5.14M48.59N/AN/A$1.05 per share1.63
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$1.63M$0.1141.5910.40N/A1.32%0.13%0.10%8/6/2025 (Estimated)
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-$257.59M-$1.23N/AN/AN/AN/A-52.98%-41.28%8/6/2025 (Estimated)
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
-$28.01MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
-$610KN/A0.00N/AN/AN/AN/AN/A

Latest VHAQ, ALLO, IMMP, and ACB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/18/2025Q4 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.11$0.07-$0.04-$0.24$88.85 million$63.34 million
5/13/2025Q1 2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-$0.28-$0.28N/A-$0.28$0.00 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
N/AN/AN/AN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/AN/AN/AN/AN/A
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.13
4.31
2.16
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
N/A
9.71
9.71
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/A
18.86
N/A
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
83.63%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2.32%
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
22.14%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
13.20%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.07%
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
75.27%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,13056.21 million56.21 millionOptionable
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
310218.73 million189.86 millionOptionable
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2,021146.04 million141.56 millionOptionable
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
25.66 million1.40 millionNot Optionable

Recent News About These Companies

Viveon Health Acquisition Corp
Clearday, Inc. (CLRD)
VHAQ-R Viveon Health Acquisition Corp.
Viveon Health Acquisition Corp. (VHAQ-RT)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$4.58 +0.11 (+2.35%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$4.57 -0.01 (-0.22%)
As of 07/3/2025 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Allogene Therapeutics stock logo

Allogene Therapeutics NASDAQ:ALLO

$1.19 -0.01 (-0.83%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$1.19 0.00 (0.00%)
As of 07/3/2025 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Prima BioMed stock logo

Prima BioMed NASDAQ:IMMP

$1.71 +0.01 (+0.59%)
As of 07/3/2025 03:31 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Viveon Health Acquisition stock logo

Viveon Health Acquisition NYSE:VHAQ

$11.00 0.00 (0.00%)
As of 01/30/2025

Viveon Health Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in the healthcare industry in North America. The company was incorporated in 2020 and is based in Atlanta, Georgia. Viveon Health Acquisition Corp. operates as a subsidiary of Viveon Health LLC.